NuCana Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • NuCana's estimated annual revenue is currently $6.8M per year.(i)
  • NuCana's estimated revenue per employee is $126,296
  • NuCana's current valuation is $148.2M. (January 2022)

Employee Data

  • NuCana has 54 Employees.(i)

NuCana's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
VP, PharmacovigilanceReveal Email/Phone
3
SVP Clinical & Medical DevelopmentReveal Email/Phone
4
Chief Financial OfficerReveal Email/Phone
5
Director Regulatory AffairsReveal Email/Phone
6
Senior Project DirectorReveal Email/Phone
7
Finance ManagerReveal Email/Phone
8
Clinical Trial AssistantReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is NuCana?

NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our phosphoramidate chemistry technology to transform some of the most widely prescribed chemotherapy agents into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid tumours, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilising our proprietary ProTide technology, we are developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.

keywords:N/A

N/A

Total Funding

54

Number of Employees

$6.8M

Revenue (est)

N/A

Employee Growth %

$148.2M

Valuation

N/A

Accelerator

NuCana News

2022-04-17 - -$0.24 EPS Expected for NuCana plc (NASDAQ:NCNA) This ...

NuCana posted earnings per share of ($0.26) in the same quarter last year, which indicates a positive year over year growth rate of 7.7%. The...

2022-03-22 - Do Traders Think NuCana PLC (NCNA) Can Keep Climbing Thursday?

NuCana PLC is a biopharmaceutical company focused on improving treatment outcome for cancer patients by ProTide technology. Utilising...

2022-03-22 - NuCana PLC (NCNA) Stock Is Higher By 13.48% This Week: Buy, Hold, or Sell?

NuCana PLC (NCNA) stock is lower by -81.05% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$16M5510%N/A
#2
$14.4M552%N/A
#3
$12M55-5%N/A
#4
$7.4M576%N/A
#5
$3.5M584%N/A